REFERNCES
  1. Colombo AL, de Almeida Júnior JN, Slavin MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect. Dis. 2017;17 : e344–e356.
  2. Russo A, Tiseo G, Falcone M, et al. Pulmonary aspergillosis: an evolving challenge for diagnosis and treatment. Infect Dis Ther. 2020;9 : 511–524.
  3. Meersseman W, Lagrou K, Maertens J, et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007; 45 : 205–216.
  4. Dandachi D, Wilson Dib R, Fernández-Cruz A, et al. Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes. Ann Med. 2018; 50 : 713–720.
  5. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 : e1–e38.
  6. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46 : 1813–1821.
  7. Peghin M, Ruiz-Camps I, Garcia-Vidal C, et al. Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. J Infect. 2014; 69 : 387–395.
  8. Dandachi D, Wilson Dib R, Fernández-Cruz A, et al. Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes. Ann Med. 2018; 50 : 713–720.
  9. Levesque E, Ait-Ammar N, Dudau D, et al. Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience. Ann Intensive Care. 2019; 9 : 31.
  10. Lahmer T, Brandl A, Rasch S, et al. Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: an observational study. Sci Rep. 2019; 9 : 11919.
  11. Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and consequences of innate immune dysfunction in cirrhosis [published correction appears in Front Immunol]. Front Immunol. 2019; 10 : 293.
  12. Garbino J, Fluckiger U, Elzi L, et al. Survey of aspergillosis in non-neutropenic patients in Swiss teaching hospitals. Clin Microbiol Infect. 2011; 17 : 1366–1371.
  13. Sipsas NV, Kontoyiannis DP. Invasive fungal infections in patients with cancer in the intensive care unit. Int J Antimicrob Agents. 2012;39 : 464–471.
  14. Bassetti M, Righi E, De Pascale G, et al. How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care. 2014;18 : 458.
  15. Dimopoulos G, Frantzeskaki F, Poulakou G, et al. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci. 2012;272 : 31–39.
  16. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation ofAspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005; 9 : R191–R199.
  17. Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in, patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010; 16 : 870–877.
  18. Höfeler H, Popescu O, Kath R, et al. Invasive bronchopulmonary aspergillosis leading to rapidly progressive respiratory failure in a patient with severe aplastic anemia. Klin Wochenschr. 1987;65 : 530–532.
  19. Vail CM, Chiles C. Invasive pulmonary aspergillosis: radiologic evidence of tracheal involvement. Radiology. 1987; 165 : 745–746.
  20. Takeda K, Imamura Y, Takazono T, et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol. 2016; 54 : 120–127.
  21. Hafeez I, Muers MF, Murphy SA, et al. Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis. Thorax. 2000; 55 : 717–719.
  22. Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J. 2006; 28 : 352–357.
  23. Haywood A, Duc J, Good P, et al. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst Rev. 2019; 2 : CD012704.
  24. Vayne-Bossert P, Haywood A, Good P, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev. 2017; 7 : CD012002.
  25. Paulsen O, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014; 32: 3221–3228.
  26. Dib RW, Khalil M, Fares J, et al. Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours. J Hosp Infect. 2020; 104 : 358–364.